IL209129A0 - Anti-pirb antibodies - Google Patents

Anti-pirb antibodies

Info

Publication number
IL209129A0
IL209129A0 IL209129A IL20912910A IL209129A0 IL 209129 A0 IL209129 A0 IL 209129A0 IL 209129 A IL209129 A IL 209129A IL 20912910 A IL20912910 A IL 20912910A IL 209129 A0 IL209129 A0 IL 209129A0
Authority
IL
Israel
Prior art keywords
pirb
antibodies
pirb antibodies
Prior art date
Application number
IL209129A
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/208,883 external-priority patent/US20100047232A1/en
Priority claimed from US12/316,130 external-priority patent/US20090232794A1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL209129A0 publication Critical patent/IL209129A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
IL209129A 2008-05-13 2010-11-04 Anti-pirb antibodies IL209129A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5294908P 2008-05-13 2008-05-13
US12/208,883 US20100047232A1 (en) 2006-11-14 2008-09-11 Modulators of neuronal regeneration
US12/316,130 US20090232794A1 (en) 2007-12-11 2008-12-09 Modulators of neuronal regeneration
PCT/US2009/043757 WO2009140361A1 (en) 2008-05-13 2009-05-13 ANTI-PirB ANTIBODIES

Publications (1)

Publication Number Publication Date
IL209129A0 true IL209129A0 (en) 2011-01-31

Family

ID=41319035

Family Applications (1)

Application Number Title Priority Date Filing Date
IL209129A IL209129A0 (en) 2008-05-13 2010-11-04 Anti-pirb antibodies

Country Status (15)

Country Link
EP (1) EP2291405A1 (en)
JP (1) JP2011523359A (en)
KR (1) KR20110011676A (en)
CN (1) CN102089327A (en)
AR (1) AR071777A1 (en)
AU (1) AU2009246443A1 (en)
BR (1) BRPI0912769A2 (en)
CA (1) CA2723430A1 (en)
IL (1) IL209129A0 (en)
MX (1) MX2010012299A (en)
PE (1) PE20091969A1 (en)
RU (1) RU2010150754A (en)
TW (1) TW200950808A (en)
WO (1) WO2009140361A1 (en)
ZA (1) ZA201007976B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013517330A (en) 2010-01-20 2013-05-16 トーラックス インコーポレイテッド Anti-ILT5 antibody and ILT5-binding antibody fragment
EP2525822B1 (en) 2010-01-20 2017-05-10 Merck Sharp & Dohme Corp. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
WO2013158748A1 (en) * 2012-04-17 2013-10-24 Mayo Foundation For Medical Education And Research Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions
CN103130898B (en) * 2013-01-28 2014-03-26 中国人民解放军第四军医大学 TAT-LBD-PEP fusion protein and application of TAT-LBD-PEP fusion protein in treatment of central nervous system lesion
AR114002A1 (en) 2017-12-22 2020-07-08 Jounce Therapeutics Inc LILRB2 ANTIBODIES
CN113056483A (en) 2018-07-09 2021-06-29 戊瑞治疗有限公司 Antibodies binding to ILT4
CN109439661B (en) * 2018-10-22 2020-10-23 西安医学院 Short hairpin shRNA (short hairpin ribonucleic acid), lentivirus and application thereof for inhibiting pirB expression
KR20230005978A (en) 2020-05-01 2023-01-10 엔지엠 바이오파마슈티컬스, 아이엔씨. ILT-binding agents and methods of their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002360376B2 (en) * 2001-11-14 2006-05-18 Immunex Corporation Modulation of LIR function to treat rheumatoid arthritis
US20090098109A1 (en) * 2006-01-23 2009-04-16 President And Fellows Of Harvard College Compositions and Methods For Enhancing Neuronal Plasticity and Regeneration

Also Published As

Publication number Publication date
AU2009246443A1 (en) 2009-11-19
CA2723430A1 (en) 2009-11-19
JP2011523359A (en) 2011-08-11
BRPI0912769A2 (en) 2015-10-13
WO2009140361A1 (en) 2009-11-19
RU2010150754A (en) 2012-06-20
TW200950808A (en) 2009-12-16
EP2291405A1 (en) 2011-03-09
PE20091969A1 (en) 2010-01-15
AR071777A1 (en) 2010-07-14
ZA201007976B (en) 2012-02-29
MX2010012299A (en) 2010-12-06
CN102089327A (en) 2011-06-08
KR20110011676A (en) 2011-02-08

Similar Documents

Publication Publication Date Title
EP3064512C0 (en) Anti-cldn6 antibody
ZA201102119B (en) Improved antibody libraies
GB0708002D0 (en) Antibodies
GB0821100D0 (en) Antibodies
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
GB0909906D0 (en) Antibodies
EP2337798A4 (en) Bsa-specific antibodies
HK1136970A1 (en) Penta-specific antibody
EP2377932A4 (en) ANTI-Siglec-15 ANTIBODY
SI2200700T1 (en) Novel antibodies
EP2138576A4 (en) Anti-claudin-4 antibody
EP2427496A4 (en) Anti-vegf-d antibodies
EP2172483A4 (en) ANTI-Muc17 ANTIBODY
GB0718737D0 (en) Antibodies
ZA201006099B (en) Anti-tyrp1 antibodies
GB0702888D0 (en) Novel Antibodies
IL205073A0 (en) Anti-bst2 antibody
GB0920324D0 (en) Antibodies
HK1170745A1 (en) Antibodies against il-17br il-17br
ZA201007976B (en) Anti-pirb antibodies
GB0818356D0 (en) Antibodies
EP2304439A4 (en) Anti-phospho-akt antibodies
EP2499256A4 (en) Anti-c-mpl antibodies
GB201015713D0 (en) Antibody